Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

328 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A.
Kruse-Jarres R, St-Louis J, Greist A, Shapiro A, Smith H, Chowdary P, Drebes A, Gomperts E, Bourgeois C, Mo M, Novack A, Farin H, Ewenstein B. Kruse-Jarres R, et al. Among authors: bourgeois c. Haemophilia. 2015 Mar;21(2):162-170. doi: 10.1111/hae.12627. Epub 2015 Jan 27. Haemophilia. 2015. PMID: 25623166 Clinical Trial.
Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.
Suez D, Stein M, Gupta S, Hussain I, Melamed I, Paris K, Darter A, Bourgeois C, Fritsch S, Leibl H, McCoy B, Gelmont D, Yel L. Suez D, et al. Among authors: bourgeois c. J Clin Immunol. 2016 Oct;36(7):700-12. doi: 10.1007/s10875-016-0327-9. Epub 2016 Aug 31. J Clin Immunol. 2016. PMID: 27582171 Free PMC article. Clinical Trial.
Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.
Borte M, Kriván G, Derfalvi B, Maródi L, Harrer T, Jolles S, Bourgeois C, Engl W, Leibl H, McCoy B, Gelmont D, Yel L. Borte M, et al. Among authors: bourgeois c. Clin Exp Immunol. 2017 Jan;187(1):146-159. doi: 10.1111/cei.12866. Epub 2016 Oct 18. Clin Exp Immunol. 2017. PMID: 27613250 Free PMC article. Clinical Trial.
Response to the Letter to the Editor Regarding "Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials".
Suez D, Stein M, Gupta S, Hussain I, Melamed I, Paris K, Darter A, Bourgeois C, Fritsch S, Leibl H, McCoy B, Gelmont D, Yel L. Suez D, et al. Among authors: bourgeois c. J Clin Immunol. 2017 Nov;37(8):739-740. doi: 10.1007/s10875-017-0438-y. Epub 2017 Sep 5. J Clin Immunol. 2017. PMID: 28875256 Free PMC article. No abstract available.
Type I Interferon Response Dysregulates Host Iron Homeostasis and Enhances Candida glabrata Infection.
Riedelberger M, Penninger P, Tscherner M, Seifert M, Jenull S, Brunnhofer C, Scheidl B, Tsymala I, Bourgeois C, Petryshyn A, Glaser W, Limbeck A, Strobl B, Weiss G, Kuchler K. Riedelberger M, et al. Among authors: bourgeois c. Cell Host Microbe. 2020 Mar 11;27(3):454-466.e8. doi: 10.1016/j.chom.2020.01.023. Epub 2020 Feb 18. Cell Host Microbe. 2020. PMID: 32075740 Free article.
328 results